TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Trading Up 1.8 %

NASDAQ:TXMD opened at $1.11 on Friday. The stock has a fifty day simple moving average of $1.42 and a 200 day simple moving average of $1.65. TherapeuticsMD has a 1-year low of $1.05 and a 1-year high of $2.75.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP grew its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.